Company:  GERON CORP (GERN)
Form Type:  SC 13G/A
Filing Date:  2/17/1998 
CIK:  0000886744 
Address:  919 EAST HILLSDALE BOULEVARD
SUITE 250
 
City, State, Zip:  FOSTER CITY, California 94404 
Telephone:  (650) 473-7700 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$2.42  
Change: 
-0.04 (-1.63%)  
Trade Time: 
Aug 05  
Market Cap: 
$913.42M
Trade GERN now with 

© 2022  
Description of Business
Geron is a late-stage clinical biopharmaceutical company that is focused on the development and potential commercialization of imetelstat, a first-in-class telomerase inhibitor. Geron's vision is to become a leader in the treatment of blood cancers, or hematologic malignancies, and is committed to improving and extending the lives of patients by changing the course of these diseases by targeting telomerase. We believe data from our prior Phase 2 clinical trials provide strong evidence that imetelstat targets telomerase to inhibit the uncontrolled proliferation of malignant stem and progenitor cells enabling recovery of bone marrow and normal blood cell production, which indicate potential disease-modifying activity. We believe this potential disease modification may differentiate imetelstat from other currently approved and investigational treatments in myeloid hematologic malignancies.
Register and access this filing in:     
  FORM SC 13G/A